Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Resonance Health Ltd ( (AU:RHT) ) is now available.
Resonance Health reported strong operational and financial momentum for the quarter ended 31 December 2025, with customer receipts of $2.9 million, positive operating cash flow and unaudited first-half FY26 revenue of $8.0 million, supported by higher-than-expected margins. Progress across its business lines included advanced recruitment in a $13.8 million major pharmaceutical clinical trial, completion of a clinical study report for another major trial, robust SaMD contract wins that have lifted forward orders and tendered pipeline above $10 million, and continued expansion of its profitable TrialsWest clinic network. The company also advanced development of its non-invasive liver fibrosis medical device, completed validation of its new “Bridge” automation technology for secure, streamlined customer workflows, and strengthened its international growth prospects with a new business development presence in India and commercial initiatives in China, all while maintaining cash balances that match its bank debt.
The most recent analyst rating on (AU:RHT) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Resonance Health Ltd stock, see the AU:RHT Stock Forecast page.
More about Resonance Health Ltd
Resonance Health Ltd is an Australian medical technology company specialising in clinical trial management services, software-as-a-medical-device (SaMD) image analysis, and clinical trial site operations under its TrialsWest brand. The company focuses on providing imaging-based solutions and contract research services to global pharmaceutical companies and healthcare providers, with growing activities in high-volume markets such as India and China.
Average Trading Volume: 295,535
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$19.47M
See more insights into RHT stock on TipRanks’ Stock Analysis page.